CNS Pharmaceuticals (NASDAQ:CNSP) Earns “Hold” Rating from Maxim Group

CNS Pharmaceuticals (NASDAQ:CNSP)‘s stock had its “hold” rating reaffirmed by research analysts at Maxim Group in a note issued to investors on Tuesday,Benzinga reports.

Separately, Alliance Global Partners raised shares of CNS Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 24th.

CNS Pharmaceuticals Trading Down 57.0 %

Shares of CNS Pharmaceuticals stock traded down $1.93 during trading hours on Tuesday, reaching $1.46. The stock had a trading volume of 1,977,876 shares, compared to its average volume of 263,057. The stock’s 50 day moving average is $4.17 and its 200 day moving average is $5.47. CNS Pharmaceuticals has a twelve month low of $2.00 and a twelve month high of $975.00. The firm has a market capitalization of $1.67 million, a PE ratio of -0.02 and a beta of 2.65.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Jane Street Group LLC boosted its holdings in CNS Pharmaceuticals by 1,712.3% in the 4th quarter. Jane Street Group LLC now owns 419,737 shares of the company’s stock valued at $51,000 after purchasing an additional 396,577 shares during the last quarter. Citadel Advisors LLC purchased a new position in CNS Pharmaceuticals in the fourth quarter worth approximately $39,000. XTX Topco Ltd acquired a new stake in CNS Pharmaceuticals during the fourth quarter worth $36,000. Connective Capital Management LLC purchased a new stake in CNS Pharmaceuticals in the fourth quarter valued at $34,000. Finally, Integrated Wealth Concepts LLC acquired a new stake in shares of CNS Pharmaceuticals during the 4th quarter worth about $30,000. Institutional investors and hedge funds own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme.